Showing 3541-3550 of 4179 results for "".
- The Election and The Marketshttps://practicaldermatology.com/news/the-election-and-the-markets/2458392/By David Mandell, JD, MBA and Robert Peelman, CFP® This presidential race is seemingly generating more interest, expressions of concern, and questions from clients than past elections. Some clients want to know how the election impacts our investment views and how we might ad
- Novan: Phase 2b Data for SB204 Gel to be Presented at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/novan-phase-2b-data-for-sb204-gel-to-be-presented-at-fall-clinical-dermatology-conference/2458396/Results from Novan’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris will be presented at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. The presentation wil
- Study Calls Attention to Negative Impact, Need for Treatment of SKhttps://practicaldermatology.com/news/study-calls-attention-to-negative-impact-need-for-treatment-of-sk/2458393/Patients with asymptomatic seborrheic keratosis (SK) are bothered by highly visible skin lesions and are very interested in treatment to improve their appearance, even if a cost were associated with treatment, according to a new study conducted in dermatology practices by Burke, Inc. on behalf of
- Biofrontera Launches Ameluz for Actinic Keratosishttps://practicaldermatology.com/news/biofrontera-launches-ameluz-for-actinic-keratosis/2458397/Biofrontera AG initiated the US commercial launch of its combination topical prescription drug Ameluz and medical device BF-RhodoLED, which has been FDA approved to treat mild to moderate actinic keratosis (AK) on the face and scalp. Ameluz is used in combination with the medical device B
- New from NeoStrata: Introducing the ProSystem Retinol Peelhttps://practicaldermatology.com/news/new-from-neostrata-the-prosystem-retinol-peel/2458398/NeoStrata is rolling out the NeoStrata ProSystem Retinol Peel, the first retinol peel for the brand. The peel contains 3% Retinol plus Retinol Boosting Complex to exfoliate and improve the appearance of fine lines and wrinkles, help reduce acne,
- Biosim Update: Pfizer to Begin Shipping INFLECTRA in Late November 2016https://practicaldermatology.com/news/biosim-update-pfizer-to-begin-shipping-inflectra-in-late-november-2016/2458400/Pfizer Inc. will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE1 (infliximab) to wholesalers in the United States in late November 2016. INFLECTRA will be the first biosimilar mono
- Sweden Greenlights Allergan's Double Chin-Melting BELKYRA®https://practicaldermatology.com/news/sweden-greenlights-allergans-double-chin-melting-belkyra/2458404/The Swedish Medical Products Agency has greenlighted Allergan’s BELKYRA® (deoxycholic acid) for submental fat reduction. BELKYRA® is already licensed in Canada, Australia, Iceland, Hungary, Austria, Lithuania, Estonia, Latvia, Romania, Bulgaria and Norway, as well
- Vaseline Initiative Aims to Close Skin Heath Treatment Gaphttps://practicaldermatology.com/news/vaseline-initiative-aims-to-close-skin-heath-treatment-gap/2458405/The Vaseline® Healing Project in partnership with non-profit Direct Relief is working to close the skin health treatment gap for Americans by providing skin care and training along with Vaseline® products and medical supplies for those with limited access.<
- Indoor Tanners Exhibit Poor Outdoor Sun Protection Practices Toohttps://practicaldermatology.com/news/indoor-tanners-exhibit-poor-outdoor-sun-protection-practices-too/2458406/Adults who frequently tan indoors aren’t great about protecting their skin outdoors or undergoing skin cancer screening either, according to a new study published online by JAMA Dermatology.
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study,